Korean J Dermatol.  1996 Feb;34(1):160-165.

Two Cases of HPV 16 - positive Bowenoid Papulosis Treated with Diphenylcyclopropenone Immunotherapy

Affiliations
  • 1Department of Dermatology, Catholic University Medical College, Seoul, Korea.
  • 2Department of Gynecology, Catholic University Medical College, Seoul, Korea.

Abstract

Bowenoid papulosis(BP) is characterized by multiple papules with a benign clinical course but having a histopathology of squamous cell carcinoma in situ on the external genitalia of sexually active men and women. It is well known that the Human papilloma virus(HPV) is connected with the development of BP. Out of these, HPV 16 which has been frequently found in the BP lesions is an oncogenic virus and the theory that BP might progress to intraepithelial neoplasia and advanced carcinoma has been postulated. Local destructive therapy including electrodessication, laser surgery, cryosurgery, and surgical excision is effective and produces a low recurrence rate. However, pain, bleeding, restriction in activity, and postoperative scars are inevitable with complete destruction of the multiple lesions. It has been suggested that diphenylcyclopropenone(DCP) might be a promising therapeutic agent for various viral diseases including HPV-related warts, It is a potent sensitizer which is not mutagenic and works by the induction of type IV hypersensitivity response in HPV infected tissue, leading to wart destruction. We herein, report 2 cases of HPV 16-positive BP treated with DCP immunotherapy.

Keyword

Bowenoid papulosis; Human papilloma virus; Diphenylcyclopropenone

MeSH Terms

Carcinoma, Squamous Cell
Cicatrix
Cryosurgery
Female
Genitalia
Hemorrhage
Human papillomavirus 16*
Humans
Hypersensitivity, Delayed
Immunotherapy*
Laser Therapy
Male
Oncogenic Viruses
Papilloma
Recurrence
Virus Diseases
Warts
Full Text Links
  • KJD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr